sharonyeo的个人主页 - 老虎社区

sharonyeo

暂无个人介绍

IP属地：未知

15关注

2粉丝

0主题

0勋章

2021-12-01

Like

A GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote>

2021-11-26

Hi

Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>

2021-11-24

Good...

抱歉，原内容已删除

2021-11-24

Ok

抱歉，原内容已删除

2021-11-24

Buy..more

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4099878636929790","uuid":"4099878636929790","gmtCreate":1636780389540,"gmtModify":1636780389540,"name":"sharonyeo","pinyin":"sharonyeo","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":15,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":603311442,"gmtCreate":1638365336291,"gmtModify":1638365336447,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603311442","repostId":"1193294379","repostType":4,"repost":{"id":"1193294379","kind":"news","pubTimestamp":1638360110,"share":"https://www.laohu8.com/m/news/1193294379?lang=zh_CN&edition=full","pubTime":"2021-12-01 20:01","market":"us","language":"en","title":"A GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1193294379","media":"Barrons","summary":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s m","content":"<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p><p><blockquote>摩根大通分析师斯蒂芬·图萨并不认为分拆会改善通用电气的命运，他再次提出了自己的观点。不过，华尔街的其他人则更为乐观。</blockquote></p><p> General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p><p><blockquote>通用电气（股票代码：GE）正在拆分为三个业务：航空航天、医疗保健和发电。首席执行官拉里·卡尔普(Larry Culp)认为，更多零件是创造股东价值的最佳方式。</blockquote></p><p> Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p><p><blockquote>重大分拆可能存在风险。持有陶氏化学(DOW)、杜邦德内穆尔(DD)和Corteva(CTVA)股票的陶氏杜邦股东已落后于市场。但如果联合技术公司的股东持有雷神技术公司（RTX）、开利全球公司（CARR）和奥的斯全球公司（OTIS）的股票，他们就跑赢了市场。</blockquote></p><p> The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p><p><blockquote>通用电气的分拆是卡尔普领导的长期扭亏为盈的一部分。他于2018年接任，并已出售资产以偿还约800亿美元的债务。</blockquote></p><p> But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p><p><blockquote>但是Tusa并不相信Culp的分手计划。图萨周二在一份报告中写道：“这一次的答案有所不同，主要围绕管理。”“今天的计划远非原创，本质上与前首席执行官弗兰纳里的计划相同。”</blockquote></p><p> Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p><p><blockquote>卡尔普接替了约翰·弗兰纳里，后者接替了杰弗里·伊梅尔特。自伊梅尔特任期后期以来，通用电气一直在苦苦挣扎。在他于2017年中期离职前大约一个月，通用电气的股价超过200美元。</blockquote></p><p> Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p><p><blockquote>图萨还对卡尔普任期初期以超过200亿美元的价格将GE biopharma出售给丹纳赫(DHR)提出质疑。他认为通用电气剩下的数百亿美元就在桌面上。通用电气确实需要筹集现金，部分原因是为多年前的保险负债提供资金。对公司来说，这不是一个好时机。</blockquote></p><p> GE declined to comment on the analyst’s note.</p><p><blockquote>通用电气拒绝对分析师的报告发表评论。</blockquote></p><p> Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p><p><blockquote>图萨和华尔街的任何人一样看空通用电气。周二的便条是他写的几封平反分手的便条之一。他对该股的评级为中性，这基本上意味着他相信他们会跟上市场的步伐，但他的目标价是每股55美元的市场低点。</blockquote></p><p> JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p><p><blockquote>摩根大通使用跑输大盘、中性和跑赢大盘评级，而不是卖出、买入和持有。摩根大通拒绝就维持中性评级发表评论，目标价远低于该股的交易价格。</blockquote></p><p> Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p><p><blockquote>华尔街的其他人就是不同意图萨的观点。美国银行分析师安德鲁·奥宾(Andrew Obin)周二在通用电气管理公司(GE management)为银行客户举办投资者看涨期权后撰写了一份研究报告。</blockquote></p><p> “Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p><p><blockquote>“我们的看涨期权专注于通用电气的大局变化，”奥宾写道。他认为卡尔普正在拆分公司，以便将运营重点放在每项业务上。“投资者的反馈普遍积极，但缺乏信心。”</blockquote></p><p> Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p><p><blockquote>投资者可能会感到紧张，但奥宾仍然看涨，将股票评级为买入。他的目标价是140美元。瑞银(UBS)分析师马库斯·米特迈尔(Markus Mittermaier)是另一位看涨通用电气他将股票评级为买入，目标价为143美元。</blockquote></p><p> On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p><p><blockquote>周一，米特迈尔写道，“三胞胎”公司未来将拥有更简单的资本结构。业务简化和债务减少是他保持乐观的两个原因。</blockquote></p><p> Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p><p><blockquote>总体而言，65%的GE分析师将股票评级为买入。标准普尔500指数股票的平均买入评级约为55%。</blockquote></p><p> GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p><p><blockquote>通用电气的股票似乎得到了大部分华尔街的支持。正如奥宾指出的那样，投资者还没有完全到位。自不到一个月前宣布分拆以来，GE股价已下跌约10%。同期，标普500和道琼斯工业平均指数分别下跌约1%和4%。</blockquote></p><p> The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p><p><blockquote>旋转需要一段时间——要到2024年才会结束。这是一个很长的等待时间，也是投资者可能出售股票的原因之一。这么长的时间也是牛熊争论将持续数月的原因。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-01 20:01</span>\n</p>\n</h4>\n</header>\n<article>\n<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p><p><blockquote>摩根大通分析师斯蒂芬·图萨并不认为分拆会改善通用电气的命运，他再次提出了自己的观点。不过，华尔街的其他人则更为乐观。</blockquote></p><p> General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p><p><blockquote>通用电气（股票代码：GE）正在拆分为三个业务：航空航天、医疗保健和发电。首席执行官拉里·卡尔普(Larry Culp)认为，更多零件是创造股东价值的最佳方式。</blockquote></p><p> Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p><p><blockquote>重大分拆可能存在风险。持有陶氏化学(DOW)、杜邦德内穆尔(DD)和Corteva(CTVA)股票的陶氏杜邦股东已落后于市场。但如果联合技术公司的股东持有雷神技术公司（RTX）、开利全球公司（CARR）和奥的斯全球公司（OTIS）的股票，他们就跑赢了市场。</blockquote></p><p> The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p><p><blockquote>通用电气的分拆是卡尔普领导的长期扭亏为盈的一部分。他于2018年接任，并已出售资产以偿还约800亿美元的债务。</blockquote></p><p> But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p><p><blockquote>但是Tusa并不相信Culp的分手计划。图萨周二在一份报告中写道：“这一次的答案有所不同，主要围绕管理。”“今天的计划远非原创，本质上与前首席执行官弗兰纳里的计划相同。”</blockquote></p><p> Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p><p><blockquote>卡尔普接替了约翰·弗兰纳里，后者接替了杰弗里·伊梅尔特。自伊梅尔特任期后期以来，通用电气一直在苦苦挣扎。在他于2017年中期离职前大约一个月，通用电气的股价超过200美元。</blockquote></p><p> Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p><p><blockquote>图萨还对卡尔普任期初期以超过200亿美元的价格将GE biopharma出售给丹纳赫(DHR)提出质疑。他认为通用电气剩下的数百亿美元就在桌面上。通用电气确实需要筹集现金，部分原因是为多年前的保险负债提供资金。对公司来说，这不是一个好时机。</blockquote></p><p> GE declined to comment on the analyst’s note.</p><p><blockquote>通用电气拒绝对分析师的报告发表评论。</blockquote></p><p> Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p><p><blockquote>图萨和华尔街的任何人一样看空通用电气。周二的便条是他写的几封平反分手的便条之一。他对该股的评级为中性，这基本上意味着他相信他们会跟上市场的步伐，但他的目标价是每股55美元的市场低点。</blockquote></p><p> JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p><p><blockquote>摩根大通使用跑输大盘、中性和跑赢大盘评级，而不是卖出、买入和持有。摩根大通拒绝就维持中性评级发表评论，目标价远低于该股的交易价格。</blockquote></p><p> Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p><p><blockquote>华尔街的其他人就是不同意图萨的观点。美国银行分析师安德鲁·奥宾(Andrew Obin)周二在通用电气管理公司(GE management)为银行客户举办投资者看涨期权后撰写了一份研究报告。</blockquote></p><p> “Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p><p><blockquote>“我们的看涨期权专注于通用电气的大局变化，”奥宾写道。他认为卡尔普正在拆分公司，以便将运营重点放在每项业务上。“投资者的反馈普遍积极，但缺乏信心。”</blockquote></p><p> Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p><p><blockquote>投资者可能会感到紧张，但奥宾仍然看涨，将股票评级为买入。他的目标价是140美元。瑞银(UBS)分析师马库斯·米特迈尔(Markus Mittermaier)是另一位看涨通用电气他将股票评级为买入，目标价为143美元。</blockquote></p><p> On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p><p><blockquote>周一，米特迈尔写道，“三胞胎”公司未来将拥有更简单的资本结构。业务简化和债务减少是他保持乐观的两个原因。</blockquote></p><p> Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p><p><blockquote>总体而言，65%的GE分析师将股票评级为买入。标准普尔500指数股票的平均买入评级约为55%。</blockquote></p><p> GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p><p><blockquote>通用电气的股票似乎得到了大部分华尔街的支持。正如奥宾指出的那样，投资者还没有完全到位。自不到一个月前宣布分拆以来，GE股价已下跌约10%。同期，标普500和道琼斯工业平均指数分别下跌约1%和4%。</blockquote></p><p> The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p><p><blockquote>旋转需要一段时间——要到2024年才会结束。这是一个很长的等待时间，也是投资者可能出售股票的原因之一。这么长的时间也是牛熊争论将持续数月的原因。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天"},"source_url":"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193294379","content_text":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) is splitting into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.\nBig breakups can be risky.DowDuPont shareholders holding shares of Dow (DOW),DuPont de Nemours (DD), and Corteva (CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of Raytheon Technologies (RTX),Carrier Global (CARR), and Otis Worldwide (OTIS).\nThe GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.\nBut Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”\nCulp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.\nTusa also questions the $20-plus billion sale of GE biopharma to Danaher (DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.\nGE declined to comment on the analyst’s note.\nTusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.\nJPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.\nOthers on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.\n“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”\nInvestors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.\nOn Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.\nOverall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%.\nGE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&P 500 and Dow Jones Industrial Average are off about 1% and 4%, respectively, over the same span.\nThe spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.","news_type":1,"symbols_score_info":{"GE":0.9}},"isVote":1,"tweetType":1,"viewCount":1679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877205404,"gmtCreate":1637932173981,"gmtModify":1637932207028,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877205404","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-26 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"RHHBY":0.9,"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":1875,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874122161,"gmtCreate":1637746176822,"gmtModify":1637746176934,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Good...","listText":"Good...","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874122161","repostId":"2185911330","repostType":4,"isVote":1,"tweetType":1,"viewCount":3579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126279,"gmtCreate":1637746118519,"gmtModify":1637746118647,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126279","repostId":"2185920330","repostType":4,"isVote":1,"tweetType":1,"viewCount":1855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126317,"gmtCreate":1637746077407,"gmtModify":1637746116009,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Buy..more","listText":"Buy..more","text":"Buy..more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126317","repostId":"1190583301","repostType":4,"isVote":1,"tweetType":1,"viewCount":2006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":603311442,"gmtCreate":1638365336291,"gmtModify":1638365336447,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603311442","repostId":"1193294379","repostType":4,"repost":{"id":"1193294379","kind":"news","pubTimestamp":1638360110,"share":"https://www.laohu8.com/m/news/1193294379?lang=zh_CN&edition=full","pubTime":"2021-12-01 20:01","market":"us","language":"en","title":"A GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1193294379","media":"Barrons","summary":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s m","content":"<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p><p><blockquote>摩根大通分析师斯蒂芬·图萨并不认为分拆会改善通用电气的命运，他再次提出了自己的观点。不过，华尔街的其他人则更为乐观。</blockquote></p><p> General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p><p><blockquote>通用电气（股票代码：GE）正在拆分为三个业务：航空航天、医疗保健和发电。首席执行官拉里·卡尔普(Larry Culp)认为，更多零件是创造股东价值的最佳方式。</blockquote></p><p> Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p><p><blockquote>重大分拆可能存在风险。持有陶氏化学(DOW)、杜邦德内穆尔(DD)和Corteva(CTVA)股票的陶氏杜邦股东已落后于市场。但如果联合技术公司的股东持有雷神技术公司（RTX）、开利全球公司（CARR）和奥的斯全球公司（OTIS）的股票，他们就跑赢了市场。</blockquote></p><p> The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p><p><blockquote>通用电气的分拆是卡尔普领导的长期扭亏为盈的一部分。他于2018年接任，并已出售资产以偿还约800亿美元的债务。</blockquote></p><p> But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p><p><blockquote>但是Tusa并不相信Culp的分手计划。图萨周二在一份报告中写道：“这一次的答案有所不同，主要围绕管理。”“今天的计划远非原创，本质上与前首席执行官弗兰纳里的计划相同。”</blockquote></p><p> Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p><p><blockquote>卡尔普接替了约翰·弗兰纳里，后者接替了杰弗里·伊梅尔特。自伊梅尔特任期后期以来，通用电气一直在苦苦挣扎。在他于2017年中期离职前大约一个月，通用电气的股价超过200美元。</blockquote></p><p> Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p><p><blockquote>图萨还对卡尔普任期初期以超过200亿美元的价格将GE biopharma出售给丹纳赫(DHR)提出质疑。他认为通用电气剩下的数百亿美元就在桌面上。通用电气确实需要筹集现金，部分原因是为多年前的保险负债提供资金。对公司来说，这不是一个好时机。</blockquote></p><p> GE declined to comment on the analyst’s note.</p><p><blockquote>通用电气拒绝对分析师的报告发表评论。</blockquote></p><p> Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p><p><blockquote>图萨和华尔街的任何人一样看空通用电气。周二的便条是他写的几封平反分手的便条之一。他对该股的评级为中性，这基本上意味着他相信他们会跟上市场的步伐，但他的目标价是每股55美元的市场低点。</blockquote></p><p> JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p><p><blockquote>摩根大通使用跑输大盘、中性和跑赢大盘评级，而不是卖出、买入和持有。摩根大通拒绝就维持中性评级发表评论，目标价远低于该股的交易价格。</blockquote></p><p> Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p><p><blockquote>华尔街的其他人就是不同意图萨的观点。美国银行分析师安德鲁·奥宾(Andrew Obin)周二在通用电气管理公司(GE management)为银行客户举办投资者看涨期权后撰写了一份研究报告。</blockquote></p><p> “Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p><p><blockquote>“我们的看涨期权专注于通用电气的大局变化，”奥宾写道。他认为卡尔普正在拆分公司，以便将运营重点放在每项业务上。“投资者的反馈普遍积极，但缺乏信心。”</blockquote></p><p> Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p><p><blockquote>投资者可能会感到紧张，但奥宾仍然看涨，将股票评级为买入。他的目标价是140美元。瑞银(UBS)分析师马库斯·米特迈尔(Markus Mittermaier)是另一位看涨通用电气他将股票评级为买入，目标价为143美元。</blockquote></p><p> On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p><p><blockquote>周一，米特迈尔写道，“三胞胎”公司未来将拥有更简单的资本结构。业务简化和债务减少是他保持乐观的两个原因。</blockquote></p><p> Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p><p><blockquote>总体而言，65%的GE分析师将股票评级为买入。标准普尔500指数股票的平均买入评级约为55%。</blockquote></p><p> GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p><p><blockquote>通用电气的股票似乎得到了大部分华尔街的支持。正如奥宾指出的那样，投资者还没有完全到位。自不到一个月前宣布分拆以来，GE股价已下跌约10%。同期，标普500和道琼斯工业平均指数分别下跌约1%和4%。</blockquote></p><p> The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p><p><blockquote>旋转需要一段时间——要到2024年才会结束。这是一个很长的等待时间，也是投资者可能出售股票的原因之一。这么长的时间也是牛熊争论将持续数月的原因。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA GE Bear Drops the Hammer Again. Why the Split Won’t Work.<blockquote>阿格熊再次落槌。为什么拆分不起作用。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-12-01 20:01</span>\n</p>\n</h4>\n</header>\n<article>\n<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p><p><blockquote>摩根大通分析师斯蒂芬·图萨并不认为分拆会改善通用电气的命运，他再次提出了自己的观点。不过，华尔街的其他人则更为乐观。</blockquote></p><p> General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p><p><blockquote>通用电气（股票代码：GE）正在拆分为三个业务：航空航天、医疗保健和发电。首席执行官拉里·卡尔普(Larry Culp)认为，更多零件是创造股东价值的最佳方式。</blockquote></p><p> Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p><p><blockquote>重大分拆可能存在风险。持有陶氏化学(DOW)、杜邦德内穆尔(DD)和Corteva(CTVA)股票的陶氏杜邦股东已落后于市场。但如果联合技术公司的股东持有雷神技术公司（RTX）、开利全球公司（CARR）和奥的斯全球公司（OTIS）的股票，他们就跑赢了市场。</blockquote></p><p> The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p><p><blockquote>通用电气的分拆是卡尔普领导的长期扭亏为盈的一部分。他于2018年接任，并已出售资产以偿还约800亿美元的债务。</blockquote></p><p> But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p><p><blockquote>但是Tusa并不相信Culp的分手计划。图萨周二在一份报告中写道：“这一次的答案有所不同，主要围绕管理。”“今天的计划远非原创，本质上与前首席执行官弗兰纳里的计划相同。”</blockquote></p><p> Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p><p><blockquote>卡尔普接替了约翰·弗兰纳里，后者接替了杰弗里·伊梅尔特。自伊梅尔特任期后期以来，通用电气一直在苦苦挣扎。在他于2017年中期离职前大约一个月，通用电气的股价超过200美元。</blockquote></p><p> Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p><p><blockquote>图萨还对卡尔普任期初期以超过200亿美元的价格将GE biopharma出售给丹纳赫(DHR)提出质疑。他认为通用电气剩下的数百亿美元就在桌面上。通用电气确实需要筹集现金，部分原因是为多年前的保险负债提供资金。对公司来说，这不是一个好时机。</blockquote></p><p> GE declined to comment on the analyst’s note.</p><p><blockquote>通用电气拒绝对分析师的报告发表评论。</blockquote></p><p> Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p><p><blockquote>图萨和华尔街的任何人一样看空通用电气。周二的便条是他写的几封平反分手的便条之一。他对该股的评级为中性，这基本上意味着他相信他们会跟上市场的步伐，但他的目标价是每股55美元的市场低点。</blockquote></p><p> JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p><p><blockquote>摩根大通使用跑输大盘、中性和跑赢大盘评级，而不是卖出、买入和持有。摩根大通拒绝就维持中性评级发表评论，目标价远低于该股的交易价格。</blockquote></p><p> Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p><p><blockquote>华尔街的其他人就是不同意图萨的观点。美国银行分析师安德鲁·奥宾(Andrew Obin)周二在通用电气管理公司(GE management)为银行客户举办投资者看涨期权后撰写了一份研究报告。</blockquote></p><p> “Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p><p><blockquote>“我们的看涨期权专注于通用电气的大局变化，”奥宾写道。他认为卡尔普正在拆分公司，以便将运营重点放在每项业务上。“投资者的反馈普遍积极，但缺乏信心。”</blockquote></p><p> Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p><p><blockquote>投资者可能会感到紧张，但奥宾仍然看涨，将股票评级为买入。他的目标价是140美元。瑞银(UBS)分析师马库斯·米特迈尔(Markus Mittermaier)是另一位看涨通用电气他将股票评级为买入，目标价为143美元。</blockquote></p><p> On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p><p><blockquote>周一，米特迈尔写道，“三胞胎”公司未来将拥有更简单的资本结构。业务简化和债务减少是他保持乐观的两个原因。</blockquote></p><p> Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p><p><blockquote>总体而言，65%的GE分析师将股票评级为买入。标准普尔500指数股票的平均买入评级约为55%。</blockquote></p><p> GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p><p><blockquote>通用电气的股票似乎得到了大部分华尔街的支持。正如奥宾指出的那样，投资者还没有完全到位。自不到一个月前宣布分拆以来，GE股价已下跌约10%。同期，标普500和道琼斯工业平均指数分别下跌约1%和4%。</blockquote></p><p> The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p><p><blockquote>旋转需要一段时间——要到2024年才会结束。这是一个很长的等待时间，也是投资者可能出售股票的原因之一。这么长的时间也是牛熊争论将持续数月的原因。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天"},"source_url":"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193294379","content_text":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) is splitting into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.\nBig breakups can be risky.DowDuPont shareholders holding shares of Dow (DOW),DuPont de Nemours (DD), and Corteva (CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of Raytheon Technologies (RTX),Carrier Global (CARR), and Otis Worldwide (OTIS).\nThe GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.\nBut Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”\nCulp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.\nTusa also questions the $20-plus billion sale of GE biopharma to Danaher (DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.\nGE declined to comment on the analyst’s note.\nTusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.\nJPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.\nOthers on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.\n“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”\nInvestors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.\nOn Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.\nOverall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%.\nGE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&P 500 and Dow Jones Industrial Average are off about 1% and 4%, respectively, over the same span.\nThe spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.","news_type":1,"symbols_score_info":{"GE":0.9}},"isVote":1,"tweetType":1,"viewCount":1679,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877205404,"gmtCreate":1637932173981,"gmtModify":1637932207028,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877205404","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=zh_CN&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake<blockquote>罗氏股东批准收购诺华207亿美元股份的交易</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-26 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p><p><blockquote>苏黎世（路透社）-瑞士制药商罗氏表示，周五，罗氏股东以压倒性多数投票支持以207亿美元收购诺华近三分之一投票权股份的交易。</blockquote></p><p> Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p><p><blockquote>罗氏召开了一次特别股东大会，以解决与两家总部位于巴塞尔的制药公司脱钩的计划相关的问题，这两家公司因这项投资而联系了二十年。</blockquote></p><p> Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p><p><blockquote>罗氏表示，股东以100.00%的多数票批准了公司截至2021年10月31日经审计的法定中期财务报表。</blockquote></p><p> They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p><p><blockquote>他们还以99.85%的多数票支持取消购买的5330万股股票的计划。</blockquote></p><p> Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p><p><blockquote>罗氏表示，因此，回购的公司法要求已经得到满足。回购交易预计将于2021年12月初完成。</blockquote></p><p> \"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p><p><blockquote>罗氏董事长Christoph Franz表示：“今天临时股东大会的决议符合罗氏的最佳经济和战略利益。”“因此，我们将能够更好地为世界各地人民的健康做出贡献。”</blockquote></p><p> Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p><p><blockquote>诺华本月早些时候同意以每股388.99美元（356.93瑞士法郎）的价格出售5330万股罗氏无记名股票，该价格反映了截至11月2日的20个交易日罗氏无投票权股票的成交量加权平均值。</blockquote></p><p> The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p><p><blockquote>购回须待股东批准通过注销购回股份削减股本及就交易编制的中期财务报表后方可作实。</blockquote></p><p> Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p><p><blockquote>诺华的参与始于2001年，当时瑞士激进投资者马丁·埃布纳(Martin Ebner)因策划了创建银行业巨头瑞银(UBS)的合并而闻名，出于对被拒绝的提议的沮丧，他将自己持有的罗氏股份提供给了其同城竞争对手。</blockquote></p><p> Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p><p><blockquote>罗氏董事长弗朗兹本月早些时候表示，这笔交易将使他的公司在战略上有更大的灵活性，因为罗氏现在可以制定计划，而不需要诺华的批准。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华","RHHBY":"罗氏控股"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"RHHBY":0.9,"NVS":0.9}},"isVote":1,"tweetType":1,"viewCount":1875,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874122161,"gmtCreate":1637746176822,"gmtModify":1637746176934,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Good...","listText":"Good...","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874122161","repostId":"2185911330","repostType":4,"isVote":1,"tweetType":1,"viewCount":3579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126279,"gmtCreate":1637746118519,"gmtModify":1637746118647,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126279","repostId":"2185920330","repostType":4,"isVote":1,"tweetType":1,"viewCount":1855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126317,"gmtCreate":1637746077407,"gmtModify":1637746116009,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099878636929790","idStr":"4099878636929790"},"themes":[],"htmlText":"Buy..more","listText":"Buy..more","text":"Buy..more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126317","repostId":"1190583301","repostType":4,"isVote":1,"tweetType":1,"viewCount":2006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}